Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

NCT06996093 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

2508

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
DRUG: aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor

Sponsor

Fudan University